- The deal builds on Sosei Heptares’ target identification and validation strategy and translational medicine approach to drug discovery, allowing the company to rapidly prioritize disease-relevant GPCR targets for structure-based drug discovery can be ranked.
TOKYO AND CAMBRIDGE, UK, December 8, 2022 (GLOBE NEWSWIRE) — Sosei Group Corporation (the “Company”), a global leader in structure-based drug discovery with a focus on G-protein coupled receptors (GPCRs) TSE: 4565) (SBDD) and Development, announced that it has entered into translational medicine and R&D agreements with the University of Oxford, UK and the MRC Weatherall Institute of Molecular Medicine, KU Leuven, Belgium. The focus of the agreement is to apply the innovative technologies and research capabilities of each academic group to identify and validate key GPCRs that cause gastrointestinal and immune disorders, including inflammatory bowel disease (IBD), as targets of SBDD , and prioritizing.
IBD is a heterogeneous chronic inflammatory disease with increasing prevalence worldwide. Between 1990 and 2017, the number of IBD patients increased from over 3.5 million he to nearly 7 million.1More than 50% of IBD patients do not respond to conventional advanced treatments, despite an expanding treatment landscape. A limited understanding of the exact proteins, cells, and mechanisms that are altered in patients with this disease, and the poorly understood heterogeneity of the disease among patients, are major reasons for treatment failure. not included.
The work of Professor Alison Simmons’ research group at the MRC Human Immunology Unit, based at the MRC Weatherall Institute of Molecular Medicine, applies state-of-the-art technology, combined with access to tissue samples from human patients, to identify GPCRs that cause chronic disease. Help clarify roles. It reduces intestinal inflammation and offers new opportunities for the treatment of IBD.
The research at KU Leuven, led by Professors Séverine Vermeire and Bram Verstockt, offers complementary multi-omics profiling approaches. It examines highly curated patient samples to provide insight into GPCR expression and function in the IBD ‘interactome’.2”. Through this study, partners will identify and confirm the biological relevance of key GPCR targets in responding and non-responding patient populations in human organoid cultures, facilitating further advances to enable precision medicine in IBD I hope that.
Alastair Brown, SVP Translational Medicine at Sosei Heptares, said: “These agreements build on our commitment to excellence in translational medicine and support our GPCR target identification and validation strategy. , can enhance the capacity of translational medicine and accelerate the opportunity to deliver novel GPCR targets for the treatment of gastrointestinal and immune diseases.Both Oxford and Leuven partners are making important innovations We believe that bringing complementary skills to Sosei Heptares will help us develop a more informed understanding of the role of GPCRs in immune diseases and accelerate future drug discovery opportunities.”
Professor Allison Simmons of the University of Oxford added: “We are excited to collaborate with Sosei Heptares to combine our respective research capabilities to explore the function of key gut GPCRs whose activity is altered in inflammation. We aim to test our findings and explore how these could aid in structure-based drug design for new therapies to promote gut health in IBD.”
Professor Séverine Vermeire, KU Leuven added: “This agreement with Sosei Heptares is evidence that a better understanding of GPCRs will have great interest and potential impact on future treatments for IBD. We are pleased to enter into this R&D agreement that provides a critical link between a major clinical academic center and a clinical-stage biopharmaceutical company focused on GPCRs and pioneering SBDD. ”
footnote
1 GBD 2017 Inflammatory bowel disease collaborators. The Lancet Gastroenterology and Hepatology.Volume 5, Issue 1, p17-30, January 1, 2020
2 The interactome is a term that refers to of whole A set of molecular interactions in a particular cell.
About Sosei Heptares
We are an international biopharmaceutical group focused on the discovery and early development of new drugs derived from our unique GPCR-targeted StaR.® Capabilities of drug discovery platforms based on technology and structure. We advance a broad and deep pipeline of new medicines across multiple therapeutic areas, including neurology, immunology, gastroenterology and inflammatory diseases.
The company has established partnerships with some of the world’s leading pharmaceutical companies and several emerging technology companies, including AbbVie, AstraZeneca, Genentech (Roche), GSK, Calliope, Neurocrine Biosciences, Novartis, Pfizer, Takeda and Verily . Sosei Heptares is headquartered in Tokyo, Japan, with corporate and R&D facilities in Cambridge, UK.
“Sosei Heptares” is the corporate brand and trademark of Sosei Group, Inc. (Ticker: 4565), which is listed on the Tokyo Stock Exchange. creation, heptares, logo, StaR® is a trademark of each company of the Sosei Group.
For more information, please visit https://www.soseiheptares.com/.
LinkedIn: @soseiheptaresco | Twitter: @soseiheptaresco | YouTube: @soseiheptaresco
inquiry:
Sosei Heptares – Information for Media and Investors
Chief Financial Officer Hironoshin Nomura
VP Investor Relations, Head of Regulatory Disclosure, Shinichiro Nishishita
Candelle Chong, SVP Investor Relations and Corporate Strategy
Japan: +81 (0)3 5210 3399 | England: +44 (0)1223 949390 | IR@SoseiHeptares.com
MEDiSTRAVA consulting (for overseas media)
Mark Swallow, Fraser Hall, Eleanor Parkin
+44 (0)203 928 6900 | SoseiHeptares@medistrava.com
